Effect of Repeated Administration of Liraglutide on Insulinogenic Indices

Status

Completed

Phase

Phase 4

Enrollment

10 participants (actual)

Sponsor

University of Tartu · Other

Design

Allocation not applicable · Open label (no masking)

Countries

1 country

Estonia

Start

Jun 2014

Primary completion

Mar 2015

Completion

Mar 2015

First posted

17 Mar 2014 (estimated)

Last update posted

1 Apr 2015 (estimated)

Conditions

Healthy

The study investigates the effect of glucagon-like peptide receptor 1 agonist, liraglutide, on insulin secretion. Study hypothesis: the effect of liraglutide on insulin release may change after repeated administration. The effect of liraglutide on insulin release will be tested using graded glucose infusion test (GGIT) in healthy volunteers. GGIT will be performed without medication and repeated 12 hours after first dose of liraglutide and after 3 weeks of treatment with liraglutide.

• Experimental

  Liraglutide

  Liraglutide 0.6 mg/day subcutaneously.

1. Change in the glucose-sensitivity of the beta cells

   Time frame · baseline, first dose, after 3-weeks on treatment

   Registry description

   Graded glucose infusion test will be used to create insulin secretion rate- plasma glucose curve. The primary outcome is the change of the slope of the curve from baseline after acute administration of liraglutide compared to the repeated administration (after 3-weeks of treatment).